Afami-cel Potential US Launch in Q3 2024; Adaptimmune’s Q4 2023 Earnings Call Summary
On Wednesday, March 6, Adaptimmune held its Q4 2023 earnings call (press release / webcast) highlighting the company’s preparation for the potential launch of afami-cel (MAGE-A4 SPEAR-T) in Q3 2024 in the US. Below, Celltelligence provides insights on the launch preparation of afami-cel upon FDA approval, while commenting on the rest of the company’s pipeline updates.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.